Project Grant R01CA298883
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $540,090 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research on epigenetic analysis of osteosarcoma. The key objectives are to: 1) Define the core regulatory circuitry driving epigenetic heterogeneity in osteosarcoma and identify transcription factor vulnerabilities for osteosarcoma subtypes using in vitro and in vivo CRISPR...
- This National Cancer Institute (NCI) Project Grant award to Georgetown University, under the Cancer Biology Research program (CFDA 93.396), provides funding of $401,115 to develop a 3D bioengineered microfluidic platform (3D-BMP) to study the mechanisms of Ewing sarcoma bone metastasis. The project aims to utilize this 3D-BMP model to perform CRISPR screens and identify key genetic drivers of Ewing sarcoma's ability to metastasize to bone, a common occurrence that is associated with poor...
- The National Cancer Institute awarded a Project Grant of $128,509 under the Cancer Research Manpower (CFDA 93.398) program to the University of California, Los Angeles (UCLA) to develop a computational system called "TreatMonitor" for comprehensive cancer monitoring using multi-omics profiling of cell-free DNA (cfDNA). The project aims to improve monitoring of minimal residual disease (MRD), recurrence, and side effects by integrating exome- and methylome-wide tumor signals in cfDNA,...
- This $452,549 Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Emory University on March 1, 2025. The grant is funding research to model and target the intrinsic and extrinsic molecular features of Myc-driven osteosarcoma, the most common bone tumor in pediatric patients. The research aims to comprehensively understand the tumor biology and identify effective therapeutic approaches, given the poor prognosis for patients with Myc-amplified...
- This Project Grant award from the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, is funded under the Cancer Research Manpower (CFDA 93.398) program. The $216,460 award to Case Western Reserve University will support research to investigate the epigenetic drivers of lung metastasis in osteosarcoma. The project aims to study the key transcription factors and chromatin state changes that enable lung colonization by osteosarcoma cells, with the goal of...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- The National Cancer Institute (NCI) awarded a $305,031 Project Grant to Round Table Research, Inc. under the Cancer Treatment Research program (CFDA 93.395) to advance extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), an aggressive form of brain cancer. The funded project, conducted in collaboration with researchers at the University of North Carolina-Chapel Hill, seeks to develop engineered tumoricidal EVs derived from induced neural stem cells (iNSCs) as a promising...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...
- The National Cancer Institute (NCI) awarded a $2,855,619 Project Grant titled "Empowering Cancer Detection and Monitoring with CAMPEX - CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles" to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), aims to advance CAMPEX, an integrated platform for highly sensitive and precise analysis of...